Liposomal delivery of hydrophobic RAMBAs provides good bioavailability and significant enhancement of retinoic acid signalling in neuroblastoma tumour cells

References

• Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003;3(3):203–216.
   PubMed Web of Science ®Google Scholar
• Matthay KK, Reynolds CP, Seeger RC, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol. 2009;27(7):1007–1013.
   PubMed Web of Science ®Google Scholar
• Sidell N. Retinoic acid-induced growth inhibition and morphologic differentiation of human neuroblastoma cells in vitro. J Natl Cancer Inst. 1982;68(4):589–596.
   PubMedGoogle Scholar
• Janesick A, Wu SC, Blumberg B. Retinoic acid signaling and neuronal differentiation. Cell Mol Life Sci. 2015;72(8):1559–1576.
   PubMed Web of Science ®Google Scholar
• Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med. 1999;341(16):1165–1173.
   PubMed Web of Science ®Google Scholar
• Veal GJ, Errington J, Rowbotham SE, et al. Adaptive dosing approaches to the individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma. Clin Cancer Res. 2013;19(2):469–479.
   PubMed Web of Science ®Google Scholar
• Stevison F, Jing J, Tripathy S, et al. Role of retinoic acid-metabolizing cytochrome P450s, CYP26, in inflammation and cancer. Adv Pharmacol. 2015;74:373–412.
   PubMedGoogle Scholar
• Nelson CH, Buttrick BR, Isoherranen N. Therapeutic potential of the inhibition of the retinoic acid hydroxylases CYP26A1 and CYP26B1 by xenobiotics. Curr Top Med Chem. 2013;13(12):1402–1428.
   PubMed Web of Science ®Google Scholar
• Thatcher JE, Zelter A, Isoherranen N. The relative importance of CYP26A1 in hepatic clearance of all-trans retinoic acid. Biochem Pharmacol. 2010;80(6):903–912.
   PubMed Web of Science ®Google Scholar
• Tang XH, Gudas LJ. Retinoids, retinoic acid receptors, and cancer. Annu Rev Pathol Mech Dis. 2011;6(1):345–364.
   PubMedGoogle Scholar
• Chapman MS. Vitamin a: history, current uses, and controversies. Semin Cutan Med Surg. 2012;31(1):11–16.
   PubMed Web of Science ®Google Scholar
• Thatcher JE, Isoherranen N. The role of CYP26 enzymes in retinoic acid clearance. Expert Opin Drug Metabol Toxicol. 2009;5(8):875–886.
   PubMed Web of Science ®Google Scholar
• Veal G, Rowbotham S, Boddy A. Pharmacokinetics and pharmacogenetics of 13-cis-retinoic acid in the treatment of neuroblastoma. Therapie. 2007;62(2):91–93.
   PubMed Web of Science ®Google Scholar
• Armstrong JL, Ruiz M, Boddy AV, et al. Increasing the intracellular availability of all-trans retinoic acid in neuroblastoma cells. Br J Cancer. 2005;92(4):696–704.
   PubMed Web of Science ®Google Scholar
• Njar VC. Cytochrome p450 retinoic acid 4-hydroxylase inhibitors: potential agents for cancer therapy. Mini Rev Med Chem. 2002;2(3):261–269.
   PubMed Web of Science ®Google Scholar
• Stevison F, Hogarth C, Tripathy S, et al. Inhibition of the all-trans retinoic acid (atRA) hydroxylases CYP26A1 and CYP26B1 results in dynamic, tissue-specific changes in endogenous atRA signaling. Drug Metab Dispos. 2017;45(7):846–854.
   PubMed Web of Science ®Google Scholar
• Lopez-Barcons L, Maurer BJ, Kang MH, et al. P450 inhibitor ketoconazole increased the intratumor drug levels and antitumor activity of fenretinide in human neuroblastoma xenograft models. Int J Cancer. 2017;141(2):405–413.
   PubMed Web of Science ®Google Scholar
• Armstrong JL, Taylor GA, Thomas HD, et al. Molecular targeting of retinoic acid metabolism in neuroblastoma: the role of the CYP26 inhibitor R116010 in vitro and in vivo. Br J Cancer. 2007;96(11):1675–1683.
   PubMed Web of Science ®Google Scholar
• Gomaa MS, Bridgens CE, Veal GJ, et al. Synthesis and biological evaluation of 3-(1H-imidazol- and triazol-1-yl)-2,2-dimethyl-3-[4-(naphthalen-2-ylamino)phenyl]propyl derivatives as small molecule inhibitors of retinoic acid 4-hydroxylase (CYP26). J Med Chem. 2011;54(19):6803–6811.
   PubMed Web of Science ®Google Scholar
• Gomaa MS, Bridgens CE, Illingworth NA, et al. Novel retinoic acid 4-hydroxylase (CYP26) inhibitors based on a 3-(1H-imidazol- and triazol-1-yl)-2,2-dimethyl-3-(4-(phenylamino)phenyl)propyl scaffold. Bioorg Med Chem. 2012;20(14):4201–4207.
   PubMed Web of Science ®Google Scholar
• Ocaya P, Gidlöf AC, Olofsson PS, et al. CYP26 inhibitor R115866 increases retinoid signaling in intimal smooth muscle cells. Arterioscler Thromb Vasc Biol. 2007;27(7):1542–1548.
   PubMed Web of Science ®Google Scholar
• Miller VA, Rigas JR, Muindi JR, et al. Modulation of all-trans retinoic acid pharmacokinetics by liarozole. Cancer Chemother Pharmacol. 1994;34(6):522–526.
   PubMed Web of Science ®Google Scholar
• Patel JB, Huynh CK, Handratta VD, et al. Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice. J Med Chem. 2004;47(27):6716–6729.
   PubMed Web of Science ®Google Scholar
• Patel JB, Mehta J, Belosay A, et al. Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth. Br J Cancer. 2007;96(8):1204–1215.
   PubMed Web of Science ®Google Scholar
• Cossu I, Bottoni G, Loi M, et al. Neuroblastoma-targeted nanocarriers improve drug delivery and penetration, delay tumor growth and abrogate metastatic diffusion. Biomaterials. 2015;68:89–99.
   PubMed Web of Science ®Google Scholar
• Pastorino F, Marimpietri D, Brignole C, et al. Ligand-targeted liposomal therapies of neuroblastoma. Curr Med Chem. 2007;14(29):3070–3078.
   PubMed Web of Science ®Google Scholar
• Bulbake U, Doppalapudi S, Kommineni N, et al. Liposomal formulations in clinical use: an updated review. Pharmaceutics. 2017;9(4):12.
   PubMed Web of Science ®Google Scholar
• Parhi P, Mohanty C, Sahoo SK. Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy. Drug Discov Today. 2012;17(17–18):1044–1052.
   PubMed Web of Science ®Google Scholar
• van der Meel R, Fens MH, Vader P, et al. Extracellular vesicles as drug delivery systems: lessons from the liposome field. J Control Release. 2014;195:72–85.
   PubMed Web of Science ®Google Scholar
• Niazi M, Zakeri-Milani P, Najafi Hajivar S, et al. Nano-based strategies to overcome p-glycoprotein-mediated drug resistance. Expert Opin Drug Metabol Toxicol. 2016;12(9):1021–1033.
   PubMed Web of Science ®Google Scholar
• Ganoth A, Merimi KC, Peer D. Overcoming multidrug resistance with nanomedicines. Expert Opin Drug Deliv. 2015;12(2):223–238.
   PubMed Web of Science ®Google Scholar
• Tagalakis AD, Maeshima R, Yu-Wai-Man C, et al. Peptide and nucleic acid-directed self-assembly of cationic nanovehicles through giant unilamellar vesicle modification: targetable nanocomplexes for in vivo nucleic acid delivery. Acta Biomater. 2017;51:351–362.
   PubMed Web of Science ®Google Scholar
• Huynh CK, Brodie AM, Njar VC. Inhibitory effects of retinoic acid metabolism blocking agents (RAMBAs) on the growth of human prostate cancer cells and LNCaP prostate tumour xenografts in SCID mice. Br J Cancer. 2006;94(4):513–523.
   PubMed Web of Science ®Google Scholar
• López-Carballo G, Moreno L, Masiá S, et al. Activation of the phosphatidylinositol 3-kinase/Akt signaling pathway by retinoic acid is required for neural differentiation of SH-SY5Y human neuroblastoma cells. J Biol Chem. 2002;277(28):25297–25304.
   PubMed Web of Science ®Google Scholar
• Qiao J, Paul P, Lee S, et al. PI3K/AKT and ERK regulate retinoic acid-induced neuroblastoma cellular differentiation. Biochem Biophys Res Commun. 2012;424(3):421–426.
   PubMed Web of Science ®Google Scholar
• Tagalakis AD, Madaan S, Larsen SD, et al. In vitro and in vivo delivery of a sustained release nanocarrier-based formulation of an MRTF/SRF inhibitor in conjunctival fibrosis. J Nanobiotechnol. 2018;16(1):97.
   PubMedGoogle Scholar
• Tagalakis AD, Grosse SM, Meng Q-H, et al. Integrin-targeted nanocomplexes for tumour specific delivery and therapy by systemic administration. Biomaterials. 2011;32(5):1370–1376.
   PubMed Web of Science ®Google Scholar
• Tagalakis AD, Kenny GD, Bienemann AS, et al. PEGylation improves the receptor-mediated transfection efficiency of peptide-targeted, self-assembling, anionic nanocomplexes. J Control Release. 2014;174:177–187.
   PubMed Web of Science ®Google Scholar
• Wada RK, Seeger RC, Reynolds CP, et al. Cell type-specific expression and negative regulation by retinoic acid of the human N-myc promoter in neuroblastoma cells. Oncogene. 1992;7(4):711–717.
   PubMed Web of Science ®Google Scholar
• Thiele CJ, Reynolds CP, Israel MA. Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature. 1985;313(6001):404–406.
   PubMed Web of Science ®Google Scholar
• Li Y, Wang J, Gao Y, et al. Relationships between liposome properties, cell membrane binding, intracellular processing, and intracellular bioavailability. AAPS J. 2011;13(4):585–597.
   PubMed Web of Science ®Google Scholar
• Lee KD, Nir S, Papahadjopoulos D. Quantitative analysis of liposome-cell interactions in vitro: rate constants of binding and endocytosis with suspension and adherent J774 cells and human monocytes. Biochemistry. 1993;32(3):889–899.
   PubMed Web of Science ®Google Scholar
• Reynolds CP, Matthay KK, Villablanca JG, et al. Retinoid therapy of high-risk neuroblastoma. Cancer Lett. 2003;197(1–2):185–192.
   PubMed Web of Science ®Google Scholar
• Roenigk HH Jr. Liver toxicity of retinoid therapy. Pharmacol Ther. 1989;40(1):145–155.
   PubMed Web of Science ®Google Scholar
• Villablanca JG, Khan AA, Avramis VI, et al. Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation. J Clin Oncol. 1995;13(4):894–901.
   PubMed Web of Science ®Google Scholar
• Muindi J, Frankel SR, Miller WH Jr., et al. Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid “resistance” in patients with acute promyelocytic leukemia. Blood. 1992;79(2):299–303.
   PubMed Web of Science ®Google Scholar
• Van Heusden J, Van Ginckel R, Bruwiere H, et al. Inhibition of all-TRANS-retinoic acid metabolism by R116010 induces antitumour activity. Br J Cancer. 2002;86(4):605–611.
   PubMed Web of Science ®Google Scholar
• Veal GJ, Cole M, Errington J, et al. Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma – a study of the United Kingdom Children's Cancer Study Group. Br J Cancer. 2007;96(3):424–431.
   PubMed Web of Science ®Google Scholar
• Khan AA, Villablanca JG, Reynolds CP, et al. Pharmacokinetic studies of 13-cis-retinoic acid in pediatric patients with neuroblastoma following bone marrow transplantation. Cancer Chemother Pharmacol. 1996;39(1–2):34–41.
   PubMed Web of Science ®Google Scholar
• Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65(1):36–48.
   PubMed Web of Science ®Google Scholar
• Tagalakis AD, Lee DH, Bienemann AS, et al. Multifunctional, self-assembling anionic peptide-lipid nanocomplexes for targeted siRNA delivery. Biomaterials. 2014;35(29):8406–8415.
   PubMed Web of Science ®Google Scholar
• Grosse SM, Tagalakis AD, Mustapa MFM, et al. Tumor-specific gene transfer with receptor-mediated nanocomplexes modified by polyethylene glycol shielding and endosomally cleavable lipid and peptide linkers. FASEB J. 2010;24(7):2301–2313.
   PubMed Web of Science ®Google Scholar
• Danhier F. To exploit the tumor microenvironment: since the EPR effect fails in the clinic, what is the future of nanomedicine? J Control Release. 2016;244(Pt A):108–121.
   PubMed Web of Science ®Google Scholar
• So PL, Fujimoto MA, Epstein EH Jr. Pharmacologic retinoid signaling and physiologic retinoic acid receptor signaling inhibit basal cell carcinoma tumorigenesis. Mol Cancer Ther. 2008;7(5):1275–1284.
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Giles F, Romaguera J, et al. Activity of interferon-alpha and isotretinoin in patients with advanced, refractory lymphoid malignancies. Cancer. 2004;100(3):574–580.
   PubMed Web of Science ®Google Scholar